Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia

Clinical Microbiology and Infection

Volumn 5, Issue 12, 1999, Pages 724-732

  Carbon, Claude ^a   Ariza, Horacio ^b   Rabie, Willem J ^c   Salvarezza, Carlos R ^d   Elkharrat, David ^e   Rangaraj, Manikam ^f   Decosta, Paola ^f  

^a BICHAT HOSPITAL   (France)

^b Hospital Mi Pueblo   (Argentina)

^c National Hospital Bloemfontein   (South Africa)

^d Hospital Centenario de Rosario   (Argentina)

^e HÔPITAL LARIBOISIÈRE   (France)

^f SANOFI   (France)

Author keywords

Amoxycillin clavulanic acid; Clinical trial; Community acquired pneumonia; Levofloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; LEVOFLOXACIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; UROGENITAL TRACT DISEASE;

EID: 0033379693     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00705.x     Document Type: Article

References (38)

1. Marnie TJ. Community-acquired pneumonia. State-of-the-art article. Clin Infect Dis 1994; 18: 501-15.
2. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618-24.
3. Ashby BL. Treatment of pneumonia: new strategies for changing pathogens. Clin Ther 1991; 13: 637-50.
4. Venkatesan P, Macfarlane JT. Epidemiology, pathogenesis and prevention of pneumonia. Curr Opin Infect Dis 1991; 4: 145-9.
5. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 1993; 341: 511-30.
6. Bartlett JC. Community-acquired pneumonia: current status. Infect Dis Clin Pract 1995; 4(suppl 4): S223-31.
7. Johnson JA. Pathogenesis of bacterial infections of the respiratory tract. Br J Biomed Sci 1995; 52: 157-61.
8. Fass RJ. Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J Antimicrob Chemother 1993; 32(suppl A): 17-27.
9. Carbon C, Leophonte P. Management of community-acquired pneumonia. J Antimicrob Chemother 1993; 32: 1-3.
10. Schutze GE, Kaplan SL, Jacobs RF. Resistant pneumococcus: a worldwide problem. Infection 1994; 22: 233-7.
11. Yee YC, Thornsberry C. Penicillin-resistant Streptococcus pneumoniae on the rise in the United States: its effect on oral cephalosporins. Antimicrob Infect Dis Newslett 1994; 13: 49-60.
12. Felmingham D, Grüneberg RN, The Alexander Project Group. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander project. J Antimicrob Chemother 1996; 38(suppl A): 1-57.
13. Langtry HD, Lamb HM. Levofloxacin. Its uses in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998; 56: 487-515.
14. Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo antibacterial activities of levofloxacin (1-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992; 36: 860-6.
15. Yamane N, Jones RN, Frei R, Hoban DJ, Pignatari AC, Marco F. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. J Chemother 1996; 6: 83-91.
16. Chien S-C, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41: 2256-60.
17. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101-19.
18. Lee LJ, Sha X, Gotfried MH, Howard JR, Dix RK, Fish DN. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. Pharmacotherapy 1998; 18: 35-41.
19. Nagai H, Yamasaki T, Matsuda M, Goto Y, Tasiro T, Nasu M. Penetration of levofloxacin into bronchoalveolar lavage fluid. Drugs 1993; 45(suppl 3): 259.
20. Nakamori Y, Miyashita Y, Nakatani I, Nakata K. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections. Drugs 1995; 49(suppl 2): 418-19.
21. DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997; 42: 206-13.
22. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-72.
23. Norrby RS. Levofloxacin 2×500 mg iv (sequential therapy iv/oral) vs ceftriaxone 1×4.0 g iv in hospitalised patients with pneumonia. Scand J Infect Dis 1998; 30: 397-404.
24. Shah P. Levofloxacin vs. cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis (AECB). J Antimicrob Chemother 1999; 43: 529-39.
25. Cunha BA. Amoxycillin/clavulanate therapy of respiratory tract infections: a microbiologic perspective. Clin Ther 1992; 14: 418-25.
26. Legnani D. Role of antibiotics in treatment of community-acquired lower respiratory tract infections. Diagn Microbiol Infect Dis 1997; 27: 41-7.
27. Neu HC, Wilson APR, Grüneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in 38 500 patients from 1979 to 1992. J Chemother 1993; 5: 67-93.
28. Makuch K, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rev 1978; 62: 1037-40.
29. Harkins RD, Albrecht R. Design and analysis of clinical trials for anti-infective drug products. Drug Infect J 1990; 4: 213-24.
30. Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Oxford: Blackwell Scientific Publications, 1987.
31. Barry AL. Antimicrobial agents for community-acquired respiratory tract infections. Infection 1995; 23(suppl 2): S59-S64.
32. Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs 1997; 53: 817-24.
33. Finch RG. The role of new quinolones in the treatment of respiratory tract infections. Drugs 1995; 49(suppl 2): 144-51.
34. Goa KL, Bryson HM, Markham A. Sparfioxacin: a review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997; 53: 700-25.
35. Portier H, May TH, the French Study Group. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community acquired pneumonia. J Antimicrob Chemother 1996; 37(suppl A): 83-91.
36. Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin/clavulanic acid and erythromycin. Eur Respir J 1995; 8: 1999-2007.
37. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991; 325: 520-1.
38. Carbon C, Léophonte P, Petitpretz P, Chauvin JP, Hazebroucq J. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia. Antimicrob Agents Chemother 1992; 36: 833-9.